These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11306151)

  • 1. Isotonic designs for phase I trials.
    Leung DH; Wang Y
    Control Clin Trials; 2001 Apr; 22(2):126-38. PubMed ID: 11306151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
    Yuan Z; Chappell R
    Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
    Chen Z; Krailo MD; Azen SP; Tighiouart M
    Contemp Clin Trials; 2010 Sep; 31(5):473-82. PubMed ID: 20609419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating lower grade toxicity information into dose finding designs.
    Iasonos A; Zohar S; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
    Wages NA; Conaway MR
    Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
    Wages NA; Fadul CE
    Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
    Yin G; Zheng S; Xu J
    J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating adverse event relatedness into dose-finding clinical trial designs.
    Darssan D; Thompson MH; Pettitt AN
    Stat Med; 2014 Mar; 33(7):1146-61. PubMed ID: 24122859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantile estimation following non-parametric phase I clinical trials with ordinal response.
    Paul RK; Rosenberger WF; Flournoy N
    Stat Med; 2004 Aug; 23(16):2483-95. PubMed ID: 15287079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-dimensional biased coin design for dual-agent dose-finding trials.
    Sun Z; Braun TM
    Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An extension of the continual reassessment method using decision theory.
    Leung DH; Wang YG
    Stat Med; 2002 Jan; 21(1):51-63. PubMed ID: 11782050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
    Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
    Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.
    Cunanan KM; Koopmeiners JS
    Contemp Clin Trials; 2018 Aug; 71():162-172. PubMed ID: 29936124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
    Braun TM; Thall PF; Nguyen H; de Lima M
    Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.